VIA
ACIU icon

Vident Investment Advisory’s AC Immune ACIU Stock Holding History

Vident Investment Advisory’s Portfolio ACIU Stock Details ACIU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-25,974
Closed -$206K – 1151
2021
Q2 		$206K Buy
+25,974
New +$180K 0.01% 1047

Other funds holding ACIU

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vident Investment Advisory's ACIU Position: Q3 2021 in Review

Vident Investment Advisory sold out of AC Immune (ACIU) in Q3 2021, closing a stake of 25,974 shares — an estimated $206K sold.

Vident Investment Advisory first reported a position in ACIU in Q2 2021 and held it in 1 quarter. The position peaked at $206K in Q2 2021. 64 funds tracked by Wall St. Rank hold ACIU as of Q3 2021.

  • Vident Investment Advisory reported no remaining AC Immune position as of Q3 2021 after selling out during the quarter.
  • Vident Investment Advisory sold 25,974 AC Immune shares in Q3 2021, an estimated $206K.
  • Vident Investment Advisory first reported a position in AC Immune in Q2 2021 and held it in 1 quarter.
  • Vident Investment Advisory's AC Immune position peaked at $206K in Q2 2021.
  • 64 funds tracked by Wall St. Rank held AC Immune as of Q3 2021.

Based on Vident Investment Advisory's 13F filing for Q3 2021, filed 12 Nov 2021.